Management of Lassa Fever: A Current Update

被引：6

作者：

Alli, Ammar ^{[1
,2
]}

Ortiz, Juan Fernando ^{[3
,4
]}

Fabara, Stephanie P. ^{[5
]}

Patel, Amrapali ^{[6
]}

Halan, Taras ^{[7
]}

机构：

[1] Tishreen Univ, Med, Fac Med, Latakia, Syria

[2] Univ Barcelona, Internal Med, Barcelona, Spain

[3] Univ San Francisco Quito, Neurol, Quito, Ecuador

[4] Larkin Community Hosp, Neurol, Miami, FL 33143 USA

[5] Univ Catolica Santiago Guayaquil, Internal Med, Guayaquil, Ecuador

[6] George Washington Univ, Publ Hlth, Washington, DC USA

[7] Ternopil Natl Med Univ, Gen Med, Ternopol, Ukraine

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 05期

关键词：

lassa fever; CLINICAL-FEATURES; RIBAVIRIN; OUTBREAK; NIGERIA; THERAPY;

D O I：

10.7759/cureus.14797

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lassa fever (LF) is on the top-priority infections list of both the Food and Drug Administration (FDA) and World Health Organization (WHO). This review explores the different treatment approaches found in the literature within the last 20 years. Even though ribavirin stands out among medication options, only one clinical trial was done to assess its efficacy in humans, which necessitated that we look in-depth about the latest updates in managing LF infection. For that matter, we used a Medical Subject Headings (MeSH) search on PubMed. Inclusion criteria included papers written in the English language and human subjects. Intravenous (IV) ribavirin is the most effective treatment for an acute infection. Post-exposure prophylaxis with oral ribavirin is recommended. There is not sufficient evidence to recommended convalescent plasma for the treatment of Lassa fever. LF continues to be left in the shade from global and scientific attention despite experts expecting a rise in current and future infections due to the Lassa fever virus (LFV).

引用

页数：8

共 21 条

[1] Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012) [J].

Ajayi, Nnennaya A. ;

Nwigwe, Chinedu G. ;

Azuogu, Ben N. ;

Onyire, Benson N. ;

Nwonwu, Elizabeth U. ;

Ogbonnaya, Lawrence U. ;

Onwe, Francis I. ;

Ekaete, Tobin ;

Guenther, Stephan ;

Ukwaja, Kingsley N. .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (11) :E1011-E1016

[2] Lassa Fever Epidemiology, Clinical Features, Diagnosis, Management and Prevention [J].

Asogun, Danny A. ;

Guenther, Stephan ;

Akpede, George O. ;

Ihekweazu, Chikwe ;

Zumla, Alimuddin .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2019, 33 (04) :933-+

[3] Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever [J].

Bausch, Daniel G. ;

Hadi, Christiane M. ;

Khan, Sheik Humarr ;

Lertora, Juan J. L. .

CLINICAL INFECTIOUS DISEASES, 2010, 51 (12) :1435-1441

[4]

Brosh-Nissimov Tal, 2016, Disaster Mil Med, V2, P8, DOI 10.1186/s40696-016-0018-3

[5]

Buba MI, 2018, AM J PUBLIC HEALTH, V108, P262, DOI [10.2105/ajph.2017.304186, 10.2105/AJPH.2017.304186]

[6] UNEXPECTED ADVERSE REACTIONS DURING A CLINICAL-TRIAL IN RURAL WEST AFRICA [J].

FISHERHOCH, SP ;

GBORIE, S ;

PARKER, L ;

HUGGINS, J .

ANTIVIRAL RESEARCH, 1992, 19 (02) :139-147

[7]

FRAME JD, 1984, T ROY SOC TROP MED H, V78, P319, DOI 10.1016/0035-9203(84)90107-X

[8]

Gowen BB, 2011, FUTURE MICROBIOL, V6, P1429, DOI [10.2217/FMB.11.132, 10.2217/fmb.11.132]

[9] Imported Lassa fever in Germany:: Surveillance and management of contact persons [J].

Haas, WH ;

Breuer, T ;

Pfaff, N ;

Schmitz, H ;

Köhler, P ;

Asper, M ;

Emmerich, P ;

Drosten, C ;

Gölnitz, U ;

Fleischer, K ;

Günther, S .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (10) :1254-1258

[10] Lassa fever diagnostics: past, present, and future [J].

Happil, Anise N. ;

Happi, Christian T. ;

Schoepp, Randal J. .

CURRENT OPINION IN VIROLOGY, 2019, 37 :132-138

← 1 2 3 →